



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Zirgan®

Common Name: ganciclovir

PDL Category: Ophthalmic Antibiotics

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Viroptic®	Preferred

Summary

Indications and Usage: Ophthalmic antiviral indicated for the treatment of acute herpetic keratitis.¹

Mechanism of Action: Inhibits DNA replication by herpes simplex viruses (HSV).¹

Dosage Forms: Ophthalmic gel: 0.15%

Recommended Dosage: One drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days.¹

Common Adverse Drug Reactions: Blurred vision, eye irritation, punctuate keratitis, conjunctival hyperemia.¹

Contraindications: None

Manufacturer: Bausch & Lomb Inc.

Analysis: Zirgan® is indicated for the treatment of acute herpetic keratitis. In the trials used to gain FDA approval, Zirgan® was compared to acyclovir ophthalmic ointment. In one open-label, randomized, controlled multi-center trial, Zirgan® was non-inferior to acyclovir. Clinical resolution at Day 7 was achieved in 77% of patients for Zirgan® vs 72% for acyclovir. In three randomized, single-masked, controlled, multi-center trials, Zirgan® was also found non-inferior to acyclovir with Day 7 clinical resolution in 72% and 69% of patients respectively. Preferred alternatives exist on the PDL which have similar clinical efficacy and that are more cost effective. It is recommended that Zirgan® be added to the Preferred Drug List as a non-preferred drug.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Zirgan® [package insert]. Tampa, FL: Bausch & Lomb Inc.; 2010.